SCHEMBL3523039

SCHEMBL3523039

O=C(O)CCc1cccc(Oc2ccc(C(F)(F)F)cc2Cl)c1

nearest known ligand 0.77

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 7/20 0.77
MRGPRX4 Q96LA9 6/20 0.53
FFAR4 Q5NUL3 3/20 0.53
SUCNR1 Q9BXA5 1/20 0.52
MEN1 O00255 1/20 0.50
TTR P02766 1/20 0.50
PPOX P50336 1/20 0.50
KMT2A Q03164 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
THRA P10827 1/20 0.49
THRB P10828 1/20 0.49
PPARG P37231 2/20 0.48
PPARD Q03181 2/20 0.48
PPARA Q07869 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10507700 0.88 FFAR1 (0.62) FFAR1MRGPRX4MEN1TTRPPOX
SCHEMBL18058920 0.87 FFAR1 (1.00) FFAR1MRGPRX4FFAR4MEN1TTR
SCHEMBL10927774 0.86 FFAR1 (0.56) FFAR1FFAR4SUCNR1TDP1THRA
SCHEMBL10507578 0.83 FFAR1 (0.56) FFAR1MRGPRX4MEN1TTRPPOX
SCHEMBL10688690 0.83 FFAR1 (0.54) FFAR1MRGPRX4PPARGPPARDPPARA
SCHEMBL10688351 0.83 FFAR1 (0.54) FFAR1MRGPRX4MEN1TTRPPOX
SCHEMBL10518526 0.82 FFAR1 (0.74) FFAR1MRGPRX4FFAR4MEN1TTR
SCHEMBL10693814 0.81 MRGPRX4 (0.52) FFAR1MRGPRX4MEN1TTRPPOX
SCHEMBL10508984 0.81 FFAR1 (0.53) FFAR1MRGPRX4MEN1TTRPPOX
SCHEMBL11260950 0.80 MRGPRX4 (0.51) FFAR1MRGPRX4MEN1TTRPPOX

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1737809-A4 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE IN TREATING METABOLIC DISORDERS AMGEN INC (US) 2007-10-17 EP claimed
US-20070142384-A1 Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders AMGEN INC. (US) 2007-06-21 US claimed
EP-1737809-A2 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE IN TREATING METABOLIC DISORDERS Amgen, Inc (US) 2007-01-03 EP claimed
US-20060004012-A1 Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders AMGEN INC. 2006-01-05 US claimed
WO-2005086661-A2 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE IN TREATING METABOLIC DISORDERS AMGEN INC. (US) 2005-09-22 WO claimed
US-7816367-B2 Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders AMGEN INC. (US) 2010-10-19 US disclosed
US-7649110-B2 Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders AMGEN INC. (US) 2010-01-19 US disclosed
EP-1737809-A4 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE IN TREATING METABOLIC DISORDERS AMGEN INC (US) 2007-10-17 EP disclosed
US-20070142384-A1 Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders AMGEN INC. (US) 2007-06-21 US disclosed
EP-1737809-A2 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE IN TREATING METABOLIC DISORDERS Amgen, Inc (US) 2007-01-03 EP disclosed
US-20060004012-A1 Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders AMGEN INC. 2006-01-05 US disclosed
WO-2005086661-A2 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE IN TREATING METABOLIC DISORDERS AMGEN INC. (US) 2005-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004012-A1 Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders PNLIP, IAPP, GPR119 FFAR1 1245/4885MRGPRX4 713/4885FFAR4 1372/4885
US-20070142384-A1 Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders PNLIP, IAPP, GPR119 FFAR1 1245/4885MRGPRX4 713/4885FFAR4 1372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.